Literature DB >> 22398102

Severity of primary sclerosing cholangitis and its impact on the clinical outcome of Crohn's disease.

Udayakumar Navaneethan1, Preethi G K Venkatesh, Bret A Lashner, Rocio Lopez, Ravi P Kiran, Bo Shen.   

Abstract

BACKGROUND AND AIM: Crohn's disease (CD) is associated with primary sclerosing cholangitis (PSC). The aim of the study was to study the association between the severity of PSC and clinical outcome of CD, comparing the course of CD in patients with PSC not needing orthotopic liver transplantation (OLT) and those requiring OLT.
METHODS: A total of 41 patients with PSC and CD seen at the Cleveland Clinic between 1985 and 2011 were included in this study. Clinical and demographic variables were obtained regarding the outcome of CD in patients with and without OLT.
RESULTS: Patients with PSC-CD were divided into two groups: 20 without OLT (non-OLT) and 21 with OLT. 18 (85.7%) of patients in the OLT group had pancolitis in contrast to 14 (70%) in the non-OLT group. (p=0.22). There were no significant differences regarding duration of CD, but the duration of PSC was longer in the OLT group [16.0±7.8 vs. 10.3±6.4, p=0.01]. The OLT and non-OLT groups did not differ in the number of CD flares [0 (0, 0) vs. 0 (0, 5), p=0.28) and need for surgery for CD [(6 (28.6%) vs. 9 (45%), p=0.27]. Colon carcinoma and dysplasia were similar in the non-OLT and OLT groups [(4 (20%) vs. 3 (13.2%), p=0.52]. On Cox regression analysis, OLT for PSC [Hazards ratio (HR) 1.2 (95% confidence interval (C.I.): 0.38-3.7, p=0.79] did not impact the risk of colectomy.
CONCLUSIONS: In contrast to UC, severe PSC requiring OLT does not appear to impact the clinical outcome of CD.
Copyright © 2011 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22398102     DOI: 10.1016/j.crohns.2011.11.020

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  7 in total

1.  Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease.

Authors:  Ashwin N Ananthakrishnan; Andrew Cagan; Vivian S Gainer; Su-Chun Cheng; Tianxi Cai; Peter Szolovits; Stanley Y Shaw; Susanne Churchill; Elizabeth W Karlson; Shawn N Murphy; Isaac Kohane; Katherine P Liao
Journal:  J Crohns Colitis       Date:  2014-02-19       Impact factor: 9.071

2.  Assessment of extraintestinal manifestations in inflammatory bowel diseases: A systematic review and a proposed guide for clinical trials.

Authors:  Lucas Guillo; Ferdinando D'Amico; Mélanie Serrero; Karine Angioi; Damien Loeuille; Antonio Costanzo; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2020-08-10       Impact factor: 4.623

3.  Primary sclerosing cholangitis and the risk of colon neoplasia in patients with Crohn's colitis.

Authors:  Udayakumar Navaneethan; Tarun Rai; Preethi Gk Venkatesh; Ravi P Kiran
Journal:  Gastroenterol Rep (Oxf)       Date:  2015-02-26

4.  Comparison of outcomes for patients with primary sclerosing cholangitis associated with ulcerative colitis and Crohn's disease.

Authors:  Udayakumar Navaneethan; Preethi Gk Venkatesh; Ramprasad Jegadeesan; Vennisvasanth Lourdusamy; Jeffrey P Hammel; Ravi P Kiran; Bo Shen
Journal:  Gastroenterol Rep (Oxf)       Date:  2014-10-29

Review 5.  Specific Features of Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.

Authors:  Fotios S Fousekis; Vasileios I Theopistos; Ioannis V Mitselos; Alexandros Skamnelos; Athanasios Kavvadias; Konstantinos H Katsanos; Dimitrios K Christodoulou
Journal:  J Clin Med Res       Date:  2019-01-05

Review 6.  Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework.

Authors:  Ayesha Shah; Graeme A Macdonald; Mark Morrison; Gerald Holtmann
Journal:  Am J Gastroenterol       Date:  2020-06       Impact factor: 12.045

7.  Systematic review and meta-analysis: the impact of co-occurring immune-mediated inflammatory diseases on the disease localization and behavior of Crohn's disease.

Authors:  Mohamed Attauabi; Mirabella Zhao; Flemming Bendtsen; Johan Burisch
Journal:  Therap Adv Gastroenterol       Date:  2021-06-22       Impact factor: 4.409

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.